Aromando Andrew 4

What Happened
Andrew Aromando, Chief Business Officer of Oncolytics Biotech Inc. (ONCY), received a grant/award on June 1, 2026 covering 260,000 derivative securities (stock options). The filing reports $0 paid at grant; the exercise price is equal to the closing price of ONCY common stock on the Nasdaq on June 1, 2026, so the options had no intrinsic value at issuance. No shares were exercised or sold as part of this transaction.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (appears timely — within the typical 2 business-day reporting window).
• Grant: 260,000 stock options; amount paid at grant reported as $0.00.
• Exercise price: equal to ONCY's closing market price on 6/1/2026 (per footnote).
• Vesting: options vest in three equal annual installments; first tranche vests June 1, 2027, subject to continued service.
• Shares owned after transaction: not disclosed in the provided details.
• Filing footnotes: F1 (exercise price = closing price 6/1/2026), F2 (3-year annual vesting beginning 6/1/2027).

Context
This was an option grant (derivative award), not a purchase or sale of shares. Because the exercise price equals the market close on the grant date, the award had no immediate in-the-money value; value to the holder depends on future stock performance and satisfying vesting conditions. Option grants are common components of executive compensation and do not by themselves indicate a buy or sell signal.